Altrika Ltd. has appointed Cranage Healthcare to distribute its Cryoskin™ and Myskin™ products in the UK. The agreement will add these cell-based burns treatments, manufactured at Altrika’s premises in Sheffield, to the range of wound and scar treatments already offered by Cranage. Altrika’s operations are licensed by the UK MHRA (Medicines and Heathcare products Regulating Agency) and HTA (Human Tissue Authority).
“We are pleased we have been able to secure the services of Cranage to take these exciting products to the market,” said Graeme Purdy, Altrika Ltd. CEO. “We are looking to grow the use of Cryoskin™ and Myskin™ in the UK, and the experience and knowledge of the sector that Cranage bring will ensure that as many patients as possible can benefit from these game-changing products.”
Cranage Director, David Bryant added “Cryoskin and Myskin offer such an improvement in treatment over existing solutions that we are delighted to add them to our portfolio of products. Together with Altrika, we can look forward to an improved outlook for those in the UK affected by severe burns.”